|
1
|
Mooranian A, Jones M, Ionescu CM, Walker D, Wagle SR, Kovacevic B, Chester J, Foster T, Johnston E, Mikov M, Al-Salami H. Advancements in Assessments of Bio-Tissue Engineering and Viable Cell Delivery Matrices Using Bile Acid-Based Pharmacological Biotechnologies. NANOMATERIALS (BASEL, SWITZERLAND) 2021; 11:1861. [PMID: 34361247 PMCID: PMC8308343 DOI: 10.3390/nano11071861] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/24/2021] [Revised: 07/07/2021] [Accepted: 07/14/2021] [Indexed: 12/18/2022]
Abstract
The utilisation of bioartificial organs is of significant interest to many due to their versatility in treating a wide range of disorders. Microencapsulation has a potentially significant role in such organs. In order to utilise microcapsules, accurate characterisation and analysis is required to assess their properties and suitability. Bioartificial organs or transplantable microdevices must also account for immunogenic considerations, which will be discussed in detail. One of the most characterized cases is the investigation into a bioartificial pancreas, including using microencapsulation of islets or other cells, and will be the focus subject of this review. Overall, this review will discuss the traditional and modern technologies which are necessary for the characterisation of properties for transplantable microdevices or organs, summarizing analysis of the microcapsule itself, cells and finally a working organ. Furthermore, immunogenic considerations of such organs are another important aspect which is addressed within this review. The various techniques, methodologies, advantages, and disadvantages will all be discussed. Hence, the purpose of this review is providing an updated examination of all processes for the analysis of a working, biocompatible artificial organ.
Collapse
Affiliation(s)
- Armin Mooranian
- The Biotechnology and Drug Development Research Laboratory, Curtin Medical School, Curtin Health Innovation Research Institute, Curtin University, Bentley, Perth, WA 6102, Australia; (A.M.); (M.J.); (C.M.I.); (D.W.); (S.R.W.); (B.K.); (J.C.); (T.F.); (E.J.)
- Hearing Therapeutics, Ear Science Institute Australia, Queen Elizabeth II Medical Centre, Nedlands, Perth, WA 6009, Australia
| | - Melissa Jones
- The Biotechnology and Drug Development Research Laboratory, Curtin Medical School, Curtin Health Innovation Research Institute, Curtin University, Bentley, Perth, WA 6102, Australia; (A.M.); (M.J.); (C.M.I.); (D.W.); (S.R.W.); (B.K.); (J.C.); (T.F.); (E.J.)
- Hearing Therapeutics, Ear Science Institute Australia, Queen Elizabeth II Medical Centre, Nedlands, Perth, WA 6009, Australia
| | - Corina Mihaela Ionescu
- The Biotechnology and Drug Development Research Laboratory, Curtin Medical School, Curtin Health Innovation Research Institute, Curtin University, Bentley, Perth, WA 6102, Australia; (A.M.); (M.J.); (C.M.I.); (D.W.); (S.R.W.); (B.K.); (J.C.); (T.F.); (E.J.)
- Hearing Therapeutics, Ear Science Institute Australia, Queen Elizabeth II Medical Centre, Nedlands, Perth, WA 6009, Australia
| | - Daniel Walker
- The Biotechnology and Drug Development Research Laboratory, Curtin Medical School, Curtin Health Innovation Research Institute, Curtin University, Bentley, Perth, WA 6102, Australia; (A.M.); (M.J.); (C.M.I.); (D.W.); (S.R.W.); (B.K.); (J.C.); (T.F.); (E.J.)
- Hearing Therapeutics, Ear Science Institute Australia, Queen Elizabeth II Medical Centre, Nedlands, Perth, WA 6009, Australia
| | - Susbin Raj Wagle
- The Biotechnology and Drug Development Research Laboratory, Curtin Medical School, Curtin Health Innovation Research Institute, Curtin University, Bentley, Perth, WA 6102, Australia; (A.M.); (M.J.); (C.M.I.); (D.W.); (S.R.W.); (B.K.); (J.C.); (T.F.); (E.J.)
- Hearing Therapeutics, Ear Science Institute Australia, Queen Elizabeth II Medical Centre, Nedlands, Perth, WA 6009, Australia
| | - Bozica Kovacevic
- The Biotechnology and Drug Development Research Laboratory, Curtin Medical School, Curtin Health Innovation Research Institute, Curtin University, Bentley, Perth, WA 6102, Australia; (A.M.); (M.J.); (C.M.I.); (D.W.); (S.R.W.); (B.K.); (J.C.); (T.F.); (E.J.)
- Hearing Therapeutics, Ear Science Institute Australia, Queen Elizabeth II Medical Centre, Nedlands, Perth, WA 6009, Australia
| | - Jacqueline Chester
- The Biotechnology and Drug Development Research Laboratory, Curtin Medical School, Curtin Health Innovation Research Institute, Curtin University, Bentley, Perth, WA 6102, Australia; (A.M.); (M.J.); (C.M.I.); (D.W.); (S.R.W.); (B.K.); (J.C.); (T.F.); (E.J.)
- Hearing Therapeutics, Ear Science Institute Australia, Queen Elizabeth II Medical Centre, Nedlands, Perth, WA 6009, Australia
| | - Thomas Foster
- The Biotechnology and Drug Development Research Laboratory, Curtin Medical School, Curtin Health Innovation Research Institute, Curtin University, Bentley, Perth, WA 6102, Australia; (A.M.); (M.J.); (C.M.I.); (D.W.); (S.R.W.); (B.K.); (J.C.); (T.F.); (E.J.)
- Hearing Therapeutics, Ear Science Institute Australia, Queen Elizabeth II Medical Centre, Nedlands, Perth, WA 6009, Australia
| | - Edan Johnston
- The Biotechnology and Drug Development Research Laboratory, Curtin Medical School, Curtin Health Innovation Research Institute, Curtin University, Bentley, Perth, WA 6102, Australia; (A.M.); (M.J.); (C.M.I.); (D.W.); (S.R.W.); (B.K.); (J.C.); (T.F.); (E.J.)
- Hearing Therapeutics, Ear Science Institute Australia, Queen Elizabeth II Medical Centre, Nedlands, Perth, WA 6009, Australia
| | - Momir Mikov
- Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Novi Sad, Hajduk Veljkova 3, 21101 Novi Sad, Serbia;
| | - Hani Al-Salami
- The Biotechnology and Drug Development Research Laboratory, Curtin Medical School, Curtin Health Innovation Research Institute, Curtin University, Bentley, Perth, WA 6102, Australia; (A.M.); (M.J.); (C.M.I.); (D.W.); (S.R.W.); (B.K.); (J.C.); (T.F.); (E.J.)
- Hearing Therapeutics, Ear Science Institute Australia, Queen Elizabeth II Medical Centre, Nedlands, Perth, WA 6009, Australia
| |
Collapse
|
|
4
|
Werner M, Schmoldt D, Hilbrig F, Jérôme V, Raup A, Zambrano K, Hübner H, Buchholz R, Freitag R. High cell density cultivation of human leukemia T cells (Jurkat cells) in semipermeable polyelectrolyte microcapsules. Eng Life Sci 2015. [DOI: 10.1002/elsc.201400186] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Affiliation(s)
- Melanie Werner
- Chair for Process BiotechnologyUniversität Bayreuth, Bayreuth Germany
| | - Daria Schmoldt
- Chair for Process BiotechnologyUniversität Bayreuth, Bayreuth Germany
| | - Frank Hilbrig
- Chair for Process BiotechnologyUniversität Bayreuth, Bayreuth Germany
| | - Valérie Jérôme
- Chair for Process BiotechnologyUniversität Bayreuth, Bayreuth Germany
| | - Alexander Raup
- Institute of Bioprocess EngineeringFriedrich‐Alexander‐Universität Erlangen‐Nürnberg, Erlangen Germany
| | - Kenny Zambrano
- Institute of Bioprocess EngineeringFriedrich‐Alexander‐Universität Erlangen‐Nürnberg, Erlangen Germany
| | - Holger Hübner
- Institute of Bioprocess EngineeringFriedrich‐Alexander‐Universität Erlangen‐Nürnberg, Erlangen Germany
| | - Rainer Buchholz
- Institute of Bioprocess EngineeringFriedrich‐Alexander‐Universität Erlangen‐Nürnberg, Erlangen Germany
| | - Ruth Freitag
- Chair for Process BiotechnologyUniversität Bayreuth, Bayreuth Germany
| |
Collapse
|
|
7
|
Rodrigues GC, Feijó DF, Bozza MT, Pan P, Vullo D, Parkkila S, Supuran CT, Capasso C, Aguiar AP, Vermelho AB. Design, Synthesis, and Evaluation of Hydroxamic Acid Derivatives as Promising Agents for the Management of Chagas Disease. J Med Chem 2013; 57:298-308. [DOI: 10.1021/jm400902y] [Citation(s) in RCA: 61] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Affiliation(s)
- Giseli Capaci Rodrigues
- Laboratório de Síntese Orgânica,
Departamento de Química, Instituto Militar de Engenharia, IME, Rio
de Janeiro, Brasil
- Laboratório Proteases
de Microrganismos, Departamento de Microbiologia, Instituto de Microbiologia Paulo de Góes, IMPG, Universidade Federal do Rio de Janeiro, UFRJ, Rio de Janeiro, Brasil
- Escola de
Ciência e Tecnologia e Programa de Pós-Graduação
em Ensino das Ciências, Universidade do Grande Rio, Unigranrio, Duque
de Caxias, Rio de Janeiro, Brasil
| | - Daniel Ferreira Feijó
- Laboratório de Inflamação e Imunidade,
Departamento de Imunologia, Instituto de Microbiologia Paulo de Góes, IMPPG, Universidade Federal do Rio de Janeiro, UFRJ, Rio
de Janeiro, Brasil
| | - Marcelo Torres Bozza
- Laboratório de Inflamação e Imunidade,
Departamento de Imunologia, Instituto de Microbiologia Paulo de Góes, IMPPG, Universidade Federal do Rio de Janeiro, UFRJ, Rio
de Janeiro, Brasil
| | - Peiwen Pan
- Institute of Biomedical
Technology, Fimlab Ltd., School of Medicine and BioMediTech, University of Tampere and Tampere University Hospital, Medisiinarinkatu 3, 33520 Tampere, Finland
| | - Daniela Vullo
- Laboratorio di Chimica Bioinorganica, Universita degli Studi di Firenze, Via della Lastruccia 3, Rm. 188, Polo Scientifico, 50019 Sesto Fiorentino, Florence, Italy
| | - Seppo Parkkila
- Institute of Biomedical
Technology, Fimlab Ltd., School of Medicine and BioMediTech, University of Tampere and Tampere University Hospital, Medisiinarinkatu 3, 33520 Tampere, Finland
| | - Claudiu T. Supuran
- Laboratorio di Chimica Bioinorganica, Universita degli Studi di Firenze, Via della Lastruccia 3, Rm. 188, Polo Scientifico, 50019 Sesto Fiorentino, Florence, Italy
- Dipartimento NEIROFARBA, Sezione di Scienze
Farmaceutiche, Universita degli Studi di Firenze, Via Ugo Schiff
6, 50019 Sesto Fiorentino, Florence, Italy
| | - Clemente Capasso
- Istituto di Biochimica delle Proteine, CNR, Via P. Castellino 111, 80131 Napoli, Italy
| | - Alcino Palermo Aguiar
- Laboratório de Síntese Orgânica,
Departamento de Química, Instituto Militar de Engenharia, IME, Rio
de Janeiro, Brasil
| | - Alane Beatriz Vermelho
- Laboratório Proteases
de Microrganismos, Departamento de Microbiologia, Instituto de Microbiologia Paulo de Góes, IMPG, Universidade Federal do Rio de Janeiro, UFRJ, Rio de Janeiro, Brasil
- Biotecnologia −
BIOINOVAR: Unidade de Bioenergia, Biocatalise e Bioprodutos, Instituto de Microbiologia Paulo de Góes, IMPG, Universidade Federal do Rio de Janeiro, UFRJ, Rio de Janeiro, Brasil
| |
Collapse
|
|
8
|
Spasojevic M, Bhujbal S, Paredes G, de Haan BJ, Schouten AJ, de Vos P. Considerations in binding diblock copolymers on hydrophilic alginate beads for providing an immunoprotective membrane. J Biomed Mater Res A 2013; 102:1887-96. [PMID: 23853069 PMCID: PMC4232034 DOI: 10.1002/jbm.a.34863] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2013] [Revised: 06/13/2013] [Accepted: 06/28/2013] [Indexed: 01/14/2023]
Abstract
Alginate-based microcapsules are being proposed for treatment of many types of diseases. A major obstacle however in the successes is that these capsules are having large lab-to-lab variations. To make the process more reproducible, we propose to cover the surface of alginate capsules with diblock polymers that can form polymer brushes. In the present study, we describe the stepwise considerations for successful application of diblock copolymer of polyethylene glycol (PEG) and poly-l-lysine (PLL) on the surface of alginate beads. Special procedures had to be designed as alginate beads are hydrophilic and most protocols are designed for hydrophobic biomaterials. The successful attachment of diblock copolymer and the presence of PEG blocks on the surface of the capsules were studied by fluorescence microscopy. Longer time periods, that is, 30–60 min, are required to achieve saturation of the surface. The block lengths influenced the strength of the capsules. Shorter PLL blocks resulted in less stable capsules. Adequate permeability of the capsules was achieved with poly(ethylene glycol)-block-poly(l-lysine hydrochloride) (PEG454-b-PLL100) diblock copolymers. The capsules were a barrier for immunoglobulin G. The PEG454-b-PLL100 capsules have similar mechanical properties as PLL capsules. Minor immune activation of nuclear factor κB in THP-1 monocytes was observed with both PLL and PEG454-b-PLL100 capsules prepared from purified alginate. Our results show that we can successfully apply block copolymers on the surface of hydrophilic alginate beads without interfering with the physicochemical properties.
Collapse
Affiliation(s)
- Milica Spasojevic
- Department of Polymer Chemistry, Zernike Institute for Advanced Materials, University of Groningen, 9747, AG Groningen, the Netherlands; Departments of Pathology and Laboratory Medicine, Section of Medical Biology, Division of Immunoendocrinology, University of Groningen, Hanzeplein 1, 9700, RB Groningen, The Netherlands
| | | | | | | | | | | |
Collapse
|